VALIDATION OF A NOVEL, SENSITIVE, AND SPECIFIC URINE-BASED TEST FOR RECURRENCE SURVEILLANCE OF PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER IN A COMPREHENSIVE MULTICENTER STUDY

Monday, March 14th, 2022

The Uromonitor test was recently validated by the scientific community in a international recognized peer-reviewed journal (Frontiers in Genetics) in a multicentric study comprising more than 300 human samples. Uromonitor presented high sensitivity (74%) and specificity (93%) in the detection of recurrence in patients under Follow-up for Non-Muscle Invasive Bladder Cancer.

The details of this study can be found at:

https://www.frontiersin.org/articles/10.3389/fgene.2019.01237/full